Month: February 2021

MONTREAL, Feb. 22, 2021 (GLOBE NEWSWIRE) — Vanstar Mining Resources Inc. (“Vanstar”, or the “Company”) (TSX.V – VSR) has renewed the appointment of Freeform Communications Inc. to conduct investor relations in Western Canada.Freeform Communications Inc. is a Vancouver based Investor Relations and Online Marketing Firm. With over ninety years of combined experience, specializing in a full range of investor relations and capital market services, Freeform has represented a wide array of public and private clients along the way and has assisted many in achieving their targeted goals.Robert Ferguson, President of Freeform Communications states: “We are delighted to be working with Vanstar and their team of professionals. We are impressed with the Company’s fundamentals and with the opportunities that lie within. We look forward...

MONTRÉAL, 22 févr. 2021 (GLOBE NEWSWIRE) — Ressources Minières Vanstar Inc. («Vanstar», ou la «Société») (TSX. V – VSR) a renouvelé la nomination de Freeform Communications Inc. pour mener des relations avec les investisseurs dans l’Ouest canadien.Freeform Communications Inc. est une firme de Vancouver qui facilite des relations avec les investisseurs et de marketing en ligne. Avec plus de 90 ans d’expérience combinée, spécialisée dans une gamme complète de relations avec les investisseurs et de services sur les marchés financiers, Freeform a représenté un grand nombre de clients publics et privés afin de les aider à atteindre leurs objectifs ciblés.Robert Ferguson, président de Freeform Communications, déclare : « Nous sommes ravis de travailler avec Vanstar et leur équipe de professionnels. Nous sommes impressionnés par...

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease did not achieve the primary endpoint, which was the count of definitive vertigo days (DVD) in Month 3 for OTIVIDEX vs. placebo for the intent-to-treat (ITT) population (n = 148; p value = 0.312) using the Negative Binomial Model. This analysis did achieve statistical significance for the per protocol (PP) population (n = 136; p value = 0.031). These results were similar using the Generalized Poisson model (p value = 0.340 for ITT and p value = 0.030 for PP).“We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking...

HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) — TC PipeLines, LP (NYSE: TCP) (the Partnership or TC PipeLines) today reiterated its support of the pending merger with TC Energy Corporation (TSX, NYSE: TRP) (TC Energy).In reaffirming its support of the pending merger, the Partnership notes that:TC PipeLines unitholders will benefit from a more stable, diversified and attractive value creation opportunity in TC Energy: TC PipeLines unitholders will become TC Energy shareholders, providing the opportunity to participate in the growth of the post-merger company. TC Energy’s valuation has proven to be more resilient during the recent challenging environment than that of TC PipeLines.The transaction is expected to enhance potential growth for the Partnership: TC Energy has greater access to capital, including a larger North American investor...

PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and MexicoGAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.“The full enrollment of PREVENT-19 is another important step in building a body of evidence to demonstrate that NVX-CoV2373 will be safe and effective across diverse, representative populations,”...

PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on March 1, 2021.Reata’s management will host a conference call on March 1, 2021 at 8:30 am ET. The conference call will be accessible by dialing (866)270-1533 (toll-free domestic) or (412)317-0797 (international) using the access code: 10152707. The webcast link is https://event.on24.com/wcc/r/3023787/38597EBB280C48468322B7487DECE1EF.Fourth quarter and full year 2020 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call...

STAMFORD, Conn., Feb. 22, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in the following upcoming investor conferences:Cowen 41st Annual Health Care Conference on Wednesday, March 3 from 11:00-11:30 a.m. ETH.C. Wainwright Global Life Sciences Conference on Tuesday, March 9 (presentation available on-demand)Barclays Global Healthcare Conference on Wednesday, March 10 from 3:35-4:00 p.m. ETWebcasts of these events can be accessed by visiting the “Events & Presentations” page within the Investors & Media section of the SpringWorks website at https://ir.springworkstx.com. A replay of the webcasts will be available...

Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021An Investigator-Initiated Trial Will Run in ParallelYAVNE, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced the initiation of a new clinical development program to evaluate its drug product candidate MWPC005 in patients with non-melanoma skin cancer. MediWound recently submitted a protocol to the FDA for a phase I/II clinical study of MWPC005 for the treatment of basal cell carcinoma (BCC) and is preparing to initiate this study in the United States in the second quarter of 2021. A phase II investigator-initiated trial of MWPC005 in non-melanoma...

Starting today, Serstech offers its customers the option to rent complete solutions for chemical identification. The solutions include instruments, substance libraries, software and accessories and allow police, border control and other customer groups to quickly increase their capabilities and efficiency.The additional values a rental solution provides are flexibility, reduced risk, no upfront investment and a much faster way to get access to modern technology. Before Serstech Rental, it could take years from when a customer became interested in Raman until they had the instruments deployed in the field. With the much quicker and far less complex rental option, the same customer will have access to state-of-the-art Raman solutions within weeks.“The main obstacle for customers who want to buy a Raman device today is the size of the initial...

EVLI BANK PLC STOCK EXCHANGE RELEASE FEBRUARY 22, 2020, 1.15 PM. (EET/EEST)The Board of Directors of Evli Bank Plc has in its meeting on January 22, 2021 approved a request of a shareholder to convert 7,600 Series A shares of Evli Bank Plc to Series B shares in accordance with Article 4 in the Articles of Association.As a result of the conversion of shares, the company’s amount of Series A shares totals 14,627,664 and the amount of Series B shares totals 9,481,756. The conversion does not affect the total amount of shares which is 24,109,420. The number of votes of the company’s shares is after the conversion 302,035,036.The conversions of shares were registered in the Trade Register on February 22, 2021. The converted shares will be listed on the Nasdaq Helsinki together with the old shares on February 23, 2021.EVLI BANK PLCJuho...